Rapamycin's Resurrection: A New Way to Target the Cancer Cell Cycle
Open Access
- 17 October 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 93 (20) , 1517-1519
- https://doi.org/10.1093/jnci/93.20.1517
Abstract
CCI-779, a close analogue of rapamycin, has shown activity against a wide range of cancers in preclinical models and in phase I trials, and seven different phase II trials are under way. Some suggest that it may be one of the most promising drugs in the anticancer pipeline.Keywords
This publication has 0 references indexed in Scilit: